NEW YORK, July 1, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA) concerning whether the board has breached its fiduciary duties to shareholders or violated the federal securities laws.
On May 21, 2014, the U.S. Food and Drug Administration issued a warning letter to STAAR stating that an inspection of the Company's facility in Monrovia, California revealed that the Company's implantable lenses manufactured there are "adulterated" in that the systems used in manufacturing, packing, storage, or installation are not in conformity with good manufacturing requirements.
Our investigation concerns whether the Company's officers and directors should be liable for the harm to STAAR. If you own STAAR shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq. Benjamin I. Sachs-Michaels, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400, (212)935-7400 Email: firstname.lastname@example.org Website: http://www.hfesq.com
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. © 2014 Harwood Feffer LLP. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP